Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04686799 · ClinicalTrials.gov registry record · Phase 1

Doxycycline for Elbow Tendinopathy

A Phase 1 study of Lateral Epicondylitis and Lateral Epicondylitis, Unspecified Elbow, sponsored by Hospital for Special Surgery, New York.

Active
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT04686799: Active Phase 1 study of Lateral Epicondylitis and Lateral Epicondylitis, Unspecified Elbow, sponsored by Hospital for Special Surgery, New York.

NCT04686799 is a Phase 1 study of Lateral Epicondylitis and Lateral Epicondylitis, Unspecified Elbow that is active but no longer recruiting, run by Hospital for Special Surgery, New York. The registered enrollment target is 25 participants, below the 124-participant average among 7 other Lateral Epicondylitis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04686799, a Phase 1 study of Lateral Epicondylitis and Lateral Epicondylitis, Unspecified Elbow, is active but no longer recruiting, sponsored by Hospital for Special Surgery, New York.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

To evaluate the feasibility of subantimicrobial -dose (SD) doxycycline to improve outcomes of nonsurgical management of elbow tendinopathy via matrix metalloproteinase (MMP) inhibition as well as evaluate if participants will be compliant to with prescribed medication and exercise treatment. Our working hypothesis is that patients with elbow tendinopathy will be receptive to treatment with SD-doxycycline and compliant with the prescribed treatment.

Primary Outcome

Compliance: At the end of the study, compliance will be calculated using the number of self-reported doses taken divided by the number of prescribed doses (twice daily x 7 days per week x 12 weeks = 168 doses).

Interventions

  • DRUG Doxycycline Hyclate 20 MG

Study Locations (1)

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2020-12-03
Est. Completion 2026-01
Phase Phase 1

What the registry record for NCT04686799 still lists

NCT04686799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 124-participant average among 7 other Lateral Epicondylitis trials with a reported enrollment target (80% lower).

The record links to 8 conditions, with Lateral Epicondylitis appearing as the primary indexed condition, and to 1 intervention - of which Doxycycline Hyclate 20 MG is the first listed.

NCT04686799 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04686799 about?

NCT04686799 is a clinical study titled "Doxycycline for Elbow Tendinopathy". To evaluate the feasibility of subantimicrobial -dose (SD) doxycycline to improve outcomes of nonsurgical management of elbow tendinopathy via matrix metalloproteinase (MMP) inhibition as well as evaluate if participants will be compliant to with prescribed medication and exercise treatment. Our wor...

What is the current status of trial NCT04686799?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-12-03. Estimated completion is 2026-01.

What conditions does trial NCT04686799 study?

This clinical trial studies the following conditions: Lateral Epicondylitis, Lateral Epicondylitis, Unspecified Elbow, Lateral Epicondylitis, Left Elbow, Lateral Epicondylitis, Right Elbow, Lateral Epicondylitis (Tennis Elbow) Bilateral.

What interventions are being tested in trial NCT04686799?

The interventions under investigation include: Doxycycline Hyclate 20 MG (DRUG).

Who is sponsoring clinical trial NCT04686799?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04686799 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lateral Epicondylitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04686799, the US trial registry maintained by the National Library of Medicine. NCT04686799 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.